---
title: "Johnson & Johnson: Business Model"
description: "Johnson & Johnson revenue by business segment and geography from its fiscal 2025 Form 10-K, with each part's share, growth and profitability explained."
canonical: https://www.getswoopr.com/stocks/companies/johnson-and-johnson/business-model/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Johnson & Johnson: Business Model & Revenue Engine

## Direct Answer

Johnson & Johnson reports revenue across 2 business segments in its fiscal 2025 Form 10-K. Innovative Medicine is the largest, with $60.4 billion of revenue (64% of the total), followed by Med Tech at $33.8 billion (36%). 57% of revenue came from the United States.

## How Does Johnson & Johnson Make Money?

Innovative Medicine supplies 64% of revenue, so Johnson & Johnson's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2024 and 2025, Med Tech grew fastest (+6.1%) and Innovative Medicine slowest (+6.0%), so the revenue mix tilts toward Med Tech while that gap lasts.

| Segment | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| Innovative Medicine | $60.4 billion | $57.0 billion | 64.1% | 6.0% |
| Med Tech | $33.8 billion | $31.9 billion | 35.9% | 6.1% |

![Bar chart of Johnson & Johnson revenue by segment for fiscal 2025: Innovative Medicine 64.1%, Med Tech 35.9%.](https://www.getswoopr.com/images/charts/johnson-and-johnson-business-model-segment-mix.webp)
*Johnson & Johnson revenue by segment as a share of total revenue, from the table above. The largest is highlighted. Select the chart to open it full size.*

## Where Does Johnson & Johnson's Revenue Come From?

Regions follow the definitions in the filing; most companies assign revenue by customer location.

| Region | FY2025 revenue | FY2024 revenue | Share of revenue | Change |
| --- | --- | --- | --- | --- |
| United States | $53.8 billion | $50.3 billion | 57.1% | 6.9% |
| Europe | $21.5 billion | $20.2 billion | 22.9% | 6.5% |
| Asia Pacific Africa | $14.0 billion | $13.6 billion | 14.9% | 3.2% |
| Western Hemisphere Excluding US | $4.9 billion | $4.7 billion | 5.2% | 3.4% |

## What the Segment Figures Do Not Show

The rows above add up to 100% of Johnson & Johnson's reported revenue for fiscal 2025; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.

## Where These Numbers Come From

Every figure on this page is a value Johnson & Johnson reported in the segment note and revenue disclosures of its Form 10-K filed February 11, 2026 (accession 0000200406-26-000016), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.

Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2025; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What are Johnson & Johnson's business segments?

In its fiscal 2025 Form 10-K, Johnson & Johnson reports revenue for Innovative Medicine and Med Tech.

### Which part of Johnson & Johnson brings in the most revenue?

Innovative Medicine, with $60.4 billion of revenue in fiscal 2025, or 64% of the total.

### How much of Johnson & Johnson's revenue comes from outside the United States?

43% in fiscal 2025, by the geographic breakdown Johnson & Johnson reports in its Form 10-K. Companies assign revenue to regions differently (customer location, shipping address or selling entity), so check the filing's definition before comparing companies.

## References

- [SEC EDGAR: JOHNSON & JOHNSON Form 10-K filed February 11, 2026](https://www.sec.gov/Archives/edgar/data/200406/000020040626000016/jnj-20251228.htm)
- [SEC EDGAR: JOHNSON & JOHNSON annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=200406&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)
- [SEC: Financial Statement Data Sets](https://www.sec.gov/data-research/sec-markets-data/financial-statement-data-sets)

## Related Pages

- [Johnson & Johnson company dossier](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/)
- [Johnson & Johnson financial metrics](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/metrics/)
- [Johnson & Johnson financial risk indicators](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/risks/)
- [Johnson & Johnson peer comparison](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/competitors/)
- [Johnson & Johnson business model and revenue mix](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**

Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).